Translated title of the contribution | Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. |
---|---|
Original language | Undefined/Unknown |
Pages (from-to) | 599-606 |
Number of pages | 8 |
Journal | British Journal of Haematology |
Volume | 155 |
Issue number | 5 |
Publication status | Published - 2011 |
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
L.H. van der Helm, C. Alhan, P.W. Wijermans, M. van Marwijk-Kooy, R. Schaafsma, B.J. Biemond, A. Beeker, M. Hoogendoorn, B.P. van Rees, O. de Weerdt, J. Wegman, W.J. Libourel, S.A. Luykx-de Bakker, M.C. Minnema, R.E. Brouwer, F. Croon-de Boer, M. Eefting, K-S.G. Jie, A.A. van de Loosdrecht, J. Koedam
Research output: Contribution to journal › Article › Academic › peer-review